Rh disease

Jump to navigation Jump to search

Template:DiseaseDisorder infobox

Rh disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rh Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rh disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rh disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rh disease

CDC on Rh disease

Rh disease in the news

Blogs on Rh disease

Directions to Hospitals Treating Rh disease

Risk calculators and risk factors for Rh disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Rh (D) disease; rhesus disease

Serology

During any pregnancy a small amount of the baby's blood can enter the mother's circulation. If the mother is Rh negative and the baby is Rh positive, the mother produces antibodies (including IgG) against the Rhesus D antigens on her baby's red blood cells. During this and subsequent pregnancies the IgG is able to pass through the placenta into the fetus and if the level of it is sufficient it will cause a Rhesus D positive fetus to develop Rh disease. The mechanism is maternal anti-D IgG passing through the placenta to the fetus causing destruction of fetal red blood cells. Generally Rhesus disease becomes worse with each additional Rhesus incompatible pregnancy.

The main and most frequent sensitizing event is child birth (about 86% of sensitized cases), but fetal blood may pass into the maternal circulation earlier during the pregnancy (about 14% of sensitized cases)[1]. Sensitizing events during pregnancy include miscarriage, therapeutic abortion, amniocentesis, ectopic pregnancy, abdominal trauma and external cephalic version.

The incidence of Rh disease in a population depends on the proportion that are rhesus negative. Many non-caucasian peoples have a very low proportion who are Rhesus negative, so the incidence of Rh disease is very low in these populations. In Caucasian populations about 1 in 10 of all pregnancies are of a Rhesus negative woman with a Rhesus positive baby. It is very rare for the first Rhesus positive baby of a Rhesus negative woman to be affected by Rh disease. The first pregnancy with a Rhesus positive baby is significant for a rhesus negative woman because she can be sensitized to the Rh positive antigen. In Caucasian populations about 13% of Rhesus negative mothers are sensitized by their first pregnancy with a rhesus positive baby. If it were not for modern prevention and treatment, about 5% of the second Rhesus positive infants of Rhesus negative woman, would result in still births or extremely sick babies and many babies who managed to survive would be severely ill. Even higher disease rates would occur in the 3rd and subsequent Rhesus positive infants of rhesus negative woman. By using anti-RhD immunoglobulin (Rho(D) Immune Globulin) the incidence is massively reduced .

Rh disease sensitization is about 10 times more likely to occur if the fetus is ABO compatible with the mother than if the mother and fetus are ABO incompatible.

Prevention

Management

History of medical advances in Rh disease

References

  1. Bowman J; et al. (1978). "Rh-immunization during pregnancy: antenatal prophylaxis". Canadian Med Ass Journal. 118: 623–627.
  • David R. Zimmerman, Rh: The Intimate History of a Disease and Its Conquest Macmillan (1973) ISBN 0-02-633530-1.
  • Landsteiner K and Weiner A (1940). An agglutinable factor in human blood recognized by immune sera for rhesus blood. Proceedings of the Society for Experimental Biology and Medicine, 43,223.
  • Levine P, Katzin E and Burnham L (1941). Isoimmunization in pregnancy: its possible bearing on the aetiology of erythroblastosis fetalis. Journal of the American Medical Association, 116, 825-7
  • Clarke C, Donohoe W, McConnell R, Woodrow J, Finn R, Krevans J et al (1963) Further experimental studies in the prevention of Rh-haemolytic disease. BMJ 979-984
  • Freda V, Gorman j, and Pollack W (1964) Successful prevention of experimental Rh sensitization in man with an anti-Rh Gamma 2-globulin antibody preparation: a preliminary report. Transfusion, 4, 26-32
  • Wallerstein H (1946). Treatment of severe erythroblastosis by simultaneous removal and replacement of blood of the newborn. Science, 103, 583-4
  • Harman C, Bowmanj, Menticoglou S and ManningF (1988). Profound fetal thrombocytopenia in Rhesus diseas: Serious hazard at intravascular transfusion. Lancet 2,741-2
  • Clarke CA, Whitfield AGW and Mollison PL (1987) Deaths from Rh haemolytic disease in England and Wales in 1984 and 1985. BMJ 294, 1001
  • Levine P and Stetson R E: Intra-group agglutination. J Am Med Assoc, 113: 126,1939

See also

Template:HDN Template:Certain conditions originating in the perinatal period


de:Rhesus-Inkompatibilität nl:Resusantagonisme


Template:WikiDoc Sources